These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39046682)

  • 21. Different classes of antibiotics exhibit disparate negative impacts on the therapeutic efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
    Qiu H; Ma QG; Chen XT; Wen X; Zhang N; Liu WM; Wang TT; Zhang LZ
    Am J Cancer Res; 2022; 12(7):3175-3184. PubMed ID: 35968357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
    Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
    Front Oncol; 2022; 12():753234. PubMed ID: 35280736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors.
    Castello A; Rossi S; Toschi L; Lopci E
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33803006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
    Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study.
    Guven DC; Acar R; Yekeduz E; Bilgetekin I; Baytemur NK; Erol C; Ceylan F; Sendur MA; Demirci U; Urun Y; Karadurmus N; Erman M; Kilickap S
    Curr Probl Cancer; 2021 Dec; 45(6):100760. PubMed ID: 34130864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibiotic exposure windows and the efficacy of immune checkpoint blockers in patients with cancer: a meta-analysis.
    Huang L; Chen X; Zhou L; Xu Q; Xie J; Zhan P; Lv T; Song Y
    Ann Palliat Med; 2021 Mar; 10(3):2709-2722. PubMed ID: 33549013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The negative effect of antibiotics on RCC patients with immunotherapy: A systematic review and meta-analysis.
    Luo Z; Hao S; Li Y; Cheng L; Zhou X; Gunes EG; Liu S; Chen J
    Front Immunol; 2022; 13():1065004. PubMed ID: 36505435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiologic colonic uptake of
    Cvetkovic L; Régis C; Richard C; Derosa L; Leblond A; Malo J; Messaoudene M; Desilets A; Belkaid W; Elkrief A; Routy B; Juneau D
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1550-1559. PubMed ID: 33128571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
    Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
    J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
    Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
    Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Percutaneous transhepatic cholangial drainage or antibiotic therapy worsens response to immunotherapy in advanced cholangiocarcinoma.
    Huang Q; Wang F; Zhang X; Liu J; Dou X; Feng R; Zhu K; Jiang S; Zhang Y; Yue J
    BMC Cancer; 2023 Jul; 23(1):657. PubMed ID: 37442960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.
    Duttagupta S; Hakozaki T; Routy B; Messaoudene M
    Curr Oncol; 2023 Oct; 30(11):9406-9427. PubMed ID: 37999101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis.
    Lurienne L; Cervesi J; Duhalde L; de Gunzburg J; Andremont A; Zalcman G; Buffet R; Bandinelli PA
    J Thorac Oncol; 2020 Jul; 15(7):1147-1159. PubMed ID: 32173463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Li F; Zhai S; Lv Z; Yuan L; Wang S; Jin D; Yi H; Fu L; Mao Y
    Front Oncol; 2022; 12():968517. PubMed ID: 36439448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors.
    Gaucher L; Adda L; Séjourné A; Joachim C; Guillaume C; Poulet C; Liabeuf S; Gras-Champel V; Masmoudi K; Houessinon A; Bennis Y; Batteux B
    Ther Adv Med Oncol; 2021; 13():17588359211000591. PubMed ID: 33796151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma.
    Fessas P; Naeem M; Pinter M; Marron TU; Szafron D; Balcar L; Saeed A; Jun T; Dharmapuri S; Gampa A; Wang Y; Khan U; Muzaffar M; Navaid M; Lee PC; Bulumulle A; Yu B; Paul S; Nimkar N; Bettinger D; Hildebrand H; Abugabal YI; Pressiani T; Personeni N; Nishida N; Kudo M; Kaseb A; Huang YH; Ang C; Pillai A; Rimassa L; Naqash AR; Sharon E; Cortellini A; Pinato DJ
    Liver Cancer; 2021 Nov; 10(6):583-592. PubMed ID: 34950181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
    Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
    Front Oncol; 2022; 12():978069. PubMed ID: 36330494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.
    Tinsley N; Zhou C; Tan G; Rack S; Lorigan P; Blackhall F; Krebs M; Carter L; Thistlethwaite F; Graham D; Cook N
    Oncologist; 2020 Jan; 25(1):55-63. PubMed ID: 31292268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study.
    Kim H; Lee JE; Hong SH; Lee MA; Kang JH; Kim IH
    BMC Cancer; 2019 Nov; 19(1):1100. PubMed ID: 31718585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.